デフォルト表紙
市場調査レポート
商品コード
1485064

バイオロジクス創薬市場-世界の産業規模、シェア、動向、機会、予測、タイプ別、方法別、製造タイプ別、地域別、競合別、2019-2029年

Biologics Drug Discovery Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Method, By Manufacture Type, By Region and Competition, 2019-2029F

出版日: | 発行: TechSci Research | ページ情報: 英文 184 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

バイオロジクス創薬市場-世界の産業規模、シェア、動向、機会、予測、タイプ別、方法別、製造タイプ別、地域別、競合別、2019-2029年
出版日: 2024年05月24日
発行: TechSci Research
ページ情報: 英文 184 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

バイオロジクス創薬の世界市場規模は2023年に82億3,000万米ドルとなり、2029年までのCAGRは7.89%で、予測期間中に着実な成長が予測されています。

世界のバイオロジクス創薬市場は、生物由来の治療薬である生物製剤の開発が重視されるようになり、製薬業界のパラダイムシフトを目の当たりにしています。モノクローナル抗体、ワクチン、遺伝子治療を含む生物製剤は、様々な疾患に対して標的を絞った革新的な治療アプローチを提供し、創薬市場の拡大を牽引しています。慢性疾患の増加、バイオテクノロジーの進歩、分子生物学への深い理解といった要因が、生物製剤研究の急増に寄与しています。新規でより効果的な治療法へのあくなき追求が、革新的な創薬手法への需要を高めています。

市場概要
予測期間 2025-2029
市場規模:2023年 82億3,000万米ドル
市場規模:2029年 128億6,000万米ドル
CAGR:2024年-2029年 7.89%
急成長セグメント 組み換えタンパク質
最大市場 北米

特定の分子経路を標的とする能力を持つ生物製剤は、従来の低分子医薬品に比べて高い有効性と副作用の軽減を示します。このため研究開発活動が活発化し、世界市場を牽引しています。ゲノミクス、プロテオミクス、バイオインフォマティクスといった技術の融合は、バイオロジクス創薬を加速する上で極めて重要な役割を果たしています。これらの技術は、疾患メカニズムの包括的な理解、潜在的な創薬ターゲットの特定、治療薬候補の最適化を可能にします。人工知能と機械学習の統合は、薬物相互作用を予測し、リード化合物を最適化することにより、創薬パイプラインの効率をさらに高めます。

製薬会社、バイオテクノロジー企業、学術機関のコラボレーションやパートナーシップは、バイオロジクス創薬におけるコラボレーション・エコシステムを育んでいます。これらのパートナーシップは、画期的な生物学的治療薬の開発を促進するために、多様な専門知識、リソース、技術を活用しています。規制状況は、生物製剤特有の課題や特徴に対応するように進化しています。厳しい規制の枠組みは、これらの複雑な治療法の安全性と有効性を保証すると同時に、その開発と承認に合理的な道筋を提供します。世界のアンメット・メディカル・ニーズ市場は、技術革新と協調的努力に後押しされて成長を続けており、アンメット・メディカル・ニーズに対応するだけでなく、医薬品開発の展望を再構築しています。個別化医療へのシフトと現在進行中の精密治療の追求は、世界中のヘルスケアと医薬品の状況を一変させる生物製剤の変革の可能性を強調しています。

市場促進要因

慢性疾患の有病率の上昇

遠隔医療と遠隔治療の普及

データの相互運用性と電子カルテ(EHRs)

主な市場課題

データのプライバシーとセキュリティに関する懸念

規制上のハードル

主な市場動向

遠隔医療とバーチャルケアの拡大

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のバイオロジクス創薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別(モノクローナル抗体、組み換えタンパク質、その他)
    • 方法別(ターゲットの特定/検証、ヒットの生成/検証、リードの特定、リードの最適化)
    • 製造タイプ別(自社、外注)
    • 地域別
    • 企業別(2023)
  • 市場マップ

第5章 アジア太平洋地域のバイオロジクス創薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 方法別
    • 製造タイプ別
    • 国別
  • アジア太平洋地域:国別分析
    • 中国
    • インド
    • オーストラリア
    • 日本
    • 韓国

第6章 欧州のバイオロジクス創薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 方法別
    • 製造タイプ別
    • 国別
  • 欧州:国別分析
    • フランス
    • ドイツ
    • スペイン
    • イタリア
    • 英国

第7章 北米のバイオロジクス創薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 方法別
    • 製造タイプ別
    • 国別
  • 北米:国別分析
    • 米国
    • メキシコ
    • カナダ

第8章 南米のバイオロジクス創薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 方法別
    • 製造タイプ別
    • 国別
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第9章 中東・アフリカのバイオロジクス創薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 方法別
    • 製造タイプ別
    • 国別
  • 中東・アフリカ:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • エジプト

第10章 市場力学

  • 促進要因
  • 課題

第11章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第12章 世界のバイオロジクス創薬市場:SWOT分析

第13章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • AbbVie, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca, Plc
  • Bayer AG
  • Bicon Ltd.
  • Boehringer Ingelheim International GmbH.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Catalent, Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 23850

Global Biologics Drug Discovery Market was valued at USD 8.23 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 7.89% through 2029. The Global Biologics Drug Discovery Market is witnessing a paradigm shift in the pharmaceutical industry, marked by a growing emphasis on the development of biologics-therapeutic drugs derived from living organisms. Biologics, including monoclonal antibodies, vaccines, and gene therapies, offer targeted and innovative treatment approaches for various diseases, driving the expansion of the drug discovery market. Factors such as the increasing prevalence of chronic diseases, advancements in biotechnology, and a deeper understanding of molecular biology contribute to the surge in biologics research. The relentless pursuit of novel and more effective treatments fuels the demand for innovative drug discovery methods.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 8.23 Billion
Market Size 2029USD 12.86 Billion
CAGR 2024-20297.89%
Fastest Growing SegmentRecombinant Proteins
Largest MarketNorth America

Biologics, with their ability to target specific molecular pathways, exhibit high efficacy and reduced side effects compared to traditional small-molecule drugs. This has led to a surge in research and development activities, propelling the global market. The convergence of technologies such as genomics, proteomics, and bioinformatics plays a pivotal role in accelerating biologics drug discovery. These technologies enable a comprehensive understanding of disease mechanisms, identification of potential drug targets, and optimization of therapeutic candidates. The integration of artificial intelligence and machine learning further enhances the efficiency of drug discovery pipelines by predicting drug interactions and optimizing lead compounds.

Collaborations and partnerships between pharmaceutical companies, biotechnology firms, and academic institutions are fostering a collaborative ecosystem in biologics drug discovery. These partnerships leverage diverse expertise, resources, and technologies to expedite the development of breakthrough biologic therapies. The regulatory landscape is evolving to accommodate the unique challenges and characteristics of biologics. Stringent regulatory frameworks ensure the safety and efficacy of these complex therapies while providing a streamlined pathway for their development and approval. As the Global Biologics Drug Discovery Market continues to grow, fueled by innovation and collaborative efforts, it not only addresses unmet medical needs but also reshapes the landscape of drug development. The shift towards personalized medicine and the ongoing pursuit of precision therapies underscore the transformative potential of biologics in revolutionizing healthcare and pharmaceutical landscapes worldwide.

Key Market Drivers

Rising Prevalence of Chronic Diseases

The Global Biologics Drug Discovery Market is significantly influenced by the rising prevalence of chronic diseases, which has become a global health challenge. Chronic conditions, including diabetes, cardiovascular diseases, respiratory disorders, and obesity, are on the rise, contributing to a growing burden on healthcare systems. Digital health technologies play a pivotal role in addressing the complexities associated with chronic diseases. These technologies offer innovative solutions for continuous monitoring, management, and personalized care delivery. The prevalence of chronic diseases is escalating due to factors such as sedentary lifestyles, unhealthy dietary habits, and an aging population.

Digital health interventions, such as mobile health apps, wearable devices, and remote patient monitoring systems, provide valuable tools for patients and healthcare providers to manage and mitigate the impact of chronic conditions. These technologies enable real-time tracking of vital signs, medication adherence, and lifestyle factors, empowering individuals to actively participate in their health management. Telehealth and virtual care platforms have emerged as crucial components of the response to the rising prevalence of chronic diseases. They facilitate remote consultations, enabling patients to connect with healthcare professionals without the need for in-person visits. This is particularly beneficial for individuals with chronic conditions who require ongoing monitoring and timely interventions.

The integration of digital health solutions into chronic disease management enhances healthcare outcomes by promoting early detection, preventive care, and personalized treatment plans. Machine learning algorithms and data analytics further contribute to the identification of patterns and trends in health data, aiding in predictive interventions and personalized care strategies. Governments, healthcare providers, and industry stakeholders are recognizing the urgency of addressing the rising prevalence of chronic diseases and are increasingly investing in digital health initiatives. The Global Biologics Drug Discovery Market is positioned to play a pivotal role in reshaping healthcare delivery models to effectively meet the challenges posed by the growing burden of chronic conditions, offering scalable and patient-centric solutions that improve overall health outcomes.

Telehealth and Telemedicine Adoption

The Global Biologics Drug Discovery Market is experiencing a transformative wave propelled by the widespread adoption of telehealth and telemedicine. These technologies, collectively known as telehealth, represent a paradigm shift in healthcare delivery, leveraging digital communication tools to connect patients with healthcare providers remotely. The adoption of telehealth has gained significant momentum, driven by factors such as technological advancements, the need for improved accessibility, and the global response to the COVID-19 pandemic. Telehealth encompasses a range of services, including virtual consultations, remote monitoring, and digital communication for healthcare purposes. The convenience and accessibility offered by telehealth have become particularly evident during the pandemic, as individuals seek alternative ways to access healthcare without the need for physical visits to healthcare facilities.

Virtual consultations enable patients to connect with healthcare professionals from the comfort of their homes, improving access to medical advice and reducing the burden on traditional healthcare infrastructures. Remote patient monitoring is another critical aspect of telehealth adoption. Wearable devices and connected health technologies allow for the continuous monitoring of vital signs, chronic conditions, and other health metrics. This real-time data transmission enables healthcare providers to track patients' health status, intervene promptly when needed, and tailor treatment plans based on individualized health insights. The accelerated adoption of telehealth is not only a response to the immediate challenges presented by the pandemic but also indicative of a broader shift in healthcare delivery models. Telehealth offers solutions to geographical barriers, enabling individuals in remote or underserved areas to access healthcare services.

It enhances the overall efficiency of healthcare delivery by reducing wait times, minimizing the need for physical infrastructure, and optimizing healthcare resources. Governments, healthcare organizations, and technology companies are actively investing in the expansion and enhancement of telehealth services. Regulatory frameworks are evolving to support and accommodate the integration of telehealth into mainstream healthcare practices. As telehealth continues to evolve, it is poised to play a central role in the Global Biologics Drug Discovery Market, driving improved patient outcomes, enhancing accessibility, and redefining the dynamics of healthcare delivery on a global scale.

Data Interoperability and Electronic Health Records (EHRs)

Data interoperability and the widespread adoption of Electronic Health Records (EHRs) are pivotal elements reshaping the landscape of the Global Biologics Drug Discovery Market. EHRs serve as comprehensive digital repositories that store patients' health information, medical history, treatment plans, and diagnostic records in electronic formats. The integration of EHRs fosters data interoperability, allowing seamless exchange and accessibility of health information across different healthcare systems and settings. Interoperability enhances care coordination by providing a unified and standardized platform for healthcare professionals to access and share patient data. This connectivity ensures continuity of care, reducing duplication of tests and minimizing medical errors. In emergency situations or when patients seek healthcare services across different providers, interoperable EHRs enable timely access to critical health information, facilitating informed decision-making. The adoption of interoperable EHRs is crucial for achieving a holistic view of a patient's health history. It allows healthcare providers to make well-informed decisions, considering the entirety of a patient's medical background. This comprehensive understanding contributes to more personalized and effective treatment strategies, ultimately improving healthcare outcomes. Interoperable EHRs play a vital role in population health management and public health initiatives.

Aggregated and anonymized data from diverse sources facilitate epidemiological studies, trend analysis, and the identification of health disparities. This data-driven approach enables proactive interventions and targeted public health campaigns. Governments and healthcare regulatory bodies globally are recognizing the importance of data interoperability and EHR adoption. Initiatives and policies are being implemented to encourage standardization and compatibility among different EHR systems. The push for interoperability aligns with the broader goals of improving healthcare quality, reducing healthcare costs, and enhancing the overall efficiency of healthcare delivery. As the Global Biologics Drug Discovery Market evolves, the seamless exchange of health information through interoperable EHRs continues to be a driving force. The integration of these digital records not only streamlines healthcare processes but also sets the foundation for advanced analytics, artificial intelligence applications, and further innovations that contribute to the ongoing transformation of the healthcare ecosystem.

Key Market Challenges

Data Privacy and Security Concerns

Data privacy and security concerns stand out as critical challenges in the evolution of the Global Biologics Drug Discovery Market. As the industry increasingly relies on digital technologies to manage and exchange sensitive health information, safeguarding patient data becomes a paramount priority. The sheer volume and nature of health data make it an attractive target for cyber threats, including hacking, data breaches, and ransomware attacks. One of the primary concerns is ensuring the confidentiality and integrity of patient information. Digital health solutions, such as electronic health records (EHRs), telehealth platforms, and mobile health apps, store a wealth of personal and health-related data. Unauthorized access to this information could lead to privacy violations, identity theft, or misuse of sensitive medical records. Maintaining stringent security measures, including robust encryption protocols and access controls, is crucial to safeguarding the privacy of individuals. The interoperability of digital health systems introduces complexities in managing data across various platforms. The lack of standardized data formats and secure data exchange protocols can create vulnerabilities in the transmission of health information.

Cybersecurity threats, evolving attack vectors, and the need for constant updates to address emerging risks pose ongoing challenges in maintaining a resilient defense against potential breaches. Compliance with data protection regulations, such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States and the General Data Protection Regulation (GDPR) in the European Union, adds another layer of complexity. Adhering to these regulations requires digital health providers to implement robust privacy policies, conduct regular risk assessments, and ensure that patients have control over their data. As the Global Biologics Drug Discovery Market continues to advance, industry stakeholders must prioritize the development and implementation of robust cybersecurity measures. Collaborative efforts between technology developers, healthcare organizations, and regulatory bodies are essential to establishing a secure digital health ecosystem that instills confidence in patients, healthcare providers, and all participants in the digital health landscape. Addressing data privacy and security concerns is not only a regulatory necessity but also fundamental to building trust and fostering the widespread adoption of digital health solutions.

Regulatory Hurdles

Navigating regulatory hurdles poses a significant challenge to the Global Biologics Drug Discovery Market. The rapid evolution of digital health technologies often outpaces the development of clear regulatory frameworks, creating a dynamic landscape where innovations must align with existing standards and compliance requirements. Regulatory agencies worldwide, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are continually adapting their guidelines to accommodate the diverse and rapidly expanding array of digital health solutions. One key regulatory challenge is defining the classification and oversight of digital health technologies. Determining which products fall under the regulatory purview, whether they are medical devices, wellness tools, or software applications, requires precision. The classification often influences the level of scrutiny, testing, and approval processes that digital health products must undergo before entering the market. Ensuring data privacy and security compliance further complicates regulatory considerations.

Striking a balance between fostering innovation and safeguarding patient information becomes intricate, especially when navigating through varying global data protection regulations, such as the General Data Protection Regulation (GDPR) in Europe. The global nature of the Biologics Drug Discovery Market adds an extra layer of complexity as companies seek to comply with different regulatory requirements across regions. Harmonizing regulations internationally is a considerable challenge, given the diversity in healthcare systems, cultural norms, and legal frameworks. The fast-paced nature of digital health innovation introduces the need for agile regulatory processes. Traditional regulatory pathways designed for pharmaceuticals or medical devices may not be adaptable to the rapid iterations and updates common in digital health applications. Striking a balance between ensuring the safety and efficacy of these technologies and allowing for timely market access requires a nuanced approach from regulatory bodies. To address these regulatory challenges, collaboration between industry stakeholders, regulatory agencies, and policymakers is essential. Proactive engagement and ongoing dialogue can help create regulatory frameworks that foster innovation while maintaining high standards of safety, efficacy, and data protection in the Global Biologics Drug Discovery Market.

Key Market Trends

Telehealth and Virtual Care Expansion

Telehealth and virtual care expansion stand as transformative trends in the Global Biologics Drug Discovery Market, reshaping the landscape of healthcare delivery. The widespread adoption of telehealth services and virtual care platforms represents a fundamental shift in how healthcare is accessed and provided. Telehealth, encompassing virtual consultations, remote monitoring, and digital communication for healthcare purposes, has become a cornerstone of modern healthcare systems. One of the key drivers of this expansion is the growing demand for accessible and convenient healthcare services. Telehealth eliminates geographical barriers, allowing patients to connect with healthcare providers from the comfort of their homes. This accessibility is particularly crucial for individuals in remote or underserved areas, enabling them to receive timely medical advice, consultations, and follow-up care. The COVID-19 pandemic has accelerated the adoption of telehealth on a global scale, emphasizing its role in ensuring healthcare continuity during times of crisis. Virtual consultations have become a safer alternative to in-person visits, reducing the risk of exposure to infectious diseases and minimizing the burden on traditional healthcare facilities.

Remote monitoring is another facet of telehealth expansion, empowering patients and healthcare providers with real-time health data. Wearable devices and connected health technologies enable continuous tracking of vital signs, chronic conditions, and other health metrics. This data-driven approach facilitates proactive interventions, personalized treatment plans, and a more comprehensive understanding of patients' health status. The growth of telehealth and virtual care is not only driven by technological advancements but also by evolving patient expectations. Individuals seek healthcare solutions that offer flexibility, convenience, and personalized experiences. Telehealth services fulfill these expectations, providing a convenient avenue for healthcare consultations, reducing travel time, and enhancing overall patient satisfaction. As telehealth continues to expand, it contributes to the ongoing transformation of healthcare delivery models. The integration of virtual care platforms into the broader digital health ecosystem fosters a more patient-centric approach, emphasizing accessibility, efficiency, and improved health outcomes on a global scale.

Segmental Insights

Type Insights

Based on Type, recombinant proteins emerged as the fastest growing segment in the Global Biologics Drug Discovery Market in 2023. This is ascribed due to tits critical role in developing therapeutic biologics. Recombinant proteins, produced through genetic engineering, serve as essential building blocks for biopharmaceuticals. They enable the creation of monoclonal antibodies, cytokines, and other complex proteins crucial for targeted therapies. The segment's dominance is further propelled by advancements in protein engineering technologies, allowing for the design and optimization of recombinant proteins with enhanced efficacy. As the demand for biologics rises in various therapeutic areas, the Recombinant Proteins segment stands out as a key driver, shaping the landscape of biologics drug discovery globally.

Method Insights

Based on method, target identification/validation segment dominated the Global Biologics Drug Discovery Market in 2023. This is because it plays a foundational role in identifying disease-associated targets for therapeutic intervention. Comprehensive understanding of specific targets allows for the development of biologics that precisely target disease pathways. Advances in genomics, proteomics, and bioinformatics bolster target identification capabilities, enhancing accuracy. As the initial step in drug discovery, efficient target identification sets the stage for successful biologics development. The segment's prominence is amplified by the continuous pursuit of novel and validated targets, making Target Identification a critical driver in shaping the global landscape of Biologics Drug Discovery.

Regional Insights

Based on region, North America dominated the global market of biologics drug discovery market in the forecast period. The region benefits from a well-established and sophisticated healthcare infrastructure, fostering advanced research and development capabilities. Major pharmaceutical and biotechnology companies headquartered in North America play a pivotal role, contributing to the innovation and commercialization of biologics. The region hosts numerous leading research institutions and academic centers dedicated to drug discovery. Robust funding mechanisms, a highly skilled workforce, and favorable regulatory frameworks further bolster North America's position. The continuous collaboration between academia and industry, coupled with significant investments in biotechnology, collectively propel the region to the forefront, solidifying its dominance in the global Biologics Drug Discovery market.

Key Market Players

AbbVie, Inc.

Astellas Pharma, Inc.

AstraZeneca PLC

Bayer AG

Bicon Ltd.

Boehringer Ingelheim International GmbH

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

Catalent, Inc.

Report Scope:

In this report, the Global Biologics Drug Discovery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biologics Drug Discovery Market, By Type:

    Monoclonal Antibodies Recombinant Proteins Others

Biologics Drug Discovery Market, By Method:

    Target Identification/validation Hit Generation/Validation Lead Identification Lead Optimization

Biologics Drug Discovery Market, By Manufacture Type:

    In-House Outsourced

Biologics Drug Discovery Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Biologics Drug Discovery Market.

Available Customizations:

Global Biologics Drug Discovery Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Biologics Drug Discovery Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Type (Monoclonal Antibodies, Recombinant Proteins, Others)
    • 4.2.2. By Method (Target Identification/ validation, Hit Generation/ Validation, Lead Identification, Lead Optimization)
    • 4.2.3. By Manufacture Type (In-House, Outsourced)
    • 4.2.4. By Region
    • 4.2.5. By Company (2023)
  • 4.3. Market Map

5. Asia Pacific Biologics Drug Discovery Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Method
    • 5.2.3. By Manufacture Type
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Biologics Drug Discovery Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Type
        • 5.3.1.2.2. By Method
        • 5.3.1.2.3. By Manufacture Type
    • 5.3.2. India Biologics Drug Discovery Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Type
        • 5.3.2.2.2. By Method
        • 5.3.2.2.3. By Manufacture Type
    • 5.3.3. Australia Biologics Drug Discovery Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Type
        • 5.3.3.2.2. By Method
        • 5.3.3.2.3. By Manufacture Type
    • 5.3.4. Japan Biologics Drug Discovery Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Type
        • 5.3.4.2.2. By Method
        • 5.3.4.2.3. By Manufacture Type
    • 5.3.5. South Korea Biologics Drug Discovery Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Type
        • 5.3.5.2.2. By Method
        • 5.3.5.2.3. By Manufacture Type

6. Europe Biologics Drug Discovery Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Method
    • 6.2.3. By Manufacture Type
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Biologics Drug Discovery Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Method
        • 6.3.1.2.3. By Manufacture Type
    • 6.3.2. Germany Biologics Drug Discovery Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Method
        • 6.3.2.2.3. By Manufacture Type
    • 6.3.3. Spain Biologics Drug Discovery Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Method
        • 6.3.3.2.3. By Manufacture Type
    • 6.3.4. Italy Biologics Drug Discovery Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By Method
        • 6.3.4.2.3. By Manufacture Type
    • 6.3.5. United Kingdom Biologics Drug Discovery Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By Method
        • 6.3.5.2.3. By Manufacture Type

7. North America Biologics Drug Discovery Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Method
    • 7.2.3. By Manufacture Type
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Biologics Drug Discovery Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Method
        • 7.3.1.2.3. By Manufacture Type
    • 7.3.2. Mexico Biologics Drug Discovery Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Method
        • 7.3.2.2.3. By Manufacture Type
    • 7.3.3. Canada Biologics Drug Discovery Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Method
        • 7.3.3.2.3. By Manufacture Type

8. South America Biologics Drug Discovery Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Method
    • 8.2.3. By Manufacture Type
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Biologics Drug Discovery Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Method
        • 8.3.1.2.3. By Manufacture Type
    • 8.3.2. Argentina Biologics Drug Discovery Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Method
        • 8.3.2.2.3. By Manufacture Type
    • 8.3.3. Colombia Biologics Drug Discovery Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Method
        • 8.3.3.2.3. By Manufacture Type

9. Middle East and Africa Biologics Drug Discovery Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Method
    • 9.2.3. By Manufacture Type
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Biologics Drug Discovery Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Method
        • 9.3.1.2.3. By Manufacture Type
    • 9.3.2. Saudi Arabia Biologics Drug Discovery Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Method
        • 9.3.2.2.3. By Manufacture Type
    • 9.3.3. UAE Biologics Drug Discovery Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Method
        • 9.3.3.2.3. By Manufacture Type
    • 9.3.4. Egypt Biologics Drug Discovery Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Type
        • 9.3.4.2.2. By Method
        • 9.3.4.2.3. By Manufacture Type

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Biologics Drug Discovery Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. AbbVie, Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (In case of listed)
    • 14.1.5. Recent Developments
    • 14.1.6. SWOT Analysis
  • 14.2. Astellas Pharma, Inc.
  • 14.3. AstraZeneca, Plc
  • 14.4. Bayer AG
  • 14.5. Bicon Ltd.
  • 14.6. Boehringer Ingelheim International GmbH.
  • 14.7. Eli Lilly and Company
  • 14.8. F. Hoffmann-La Roche AG
  • 14.9. Gilead Sciences, Inc.
  • 14.10. Catalent, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer